Product Code: RP-ID-10216576 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10216576
Market Overview:
Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, Mexico, France, Germany, Italy, Spain, China, India, Japan) 2022-2030
" The global overactive bladder market is estimated to be valued at ~USD 6 billion by the end of 2021 and is projected to expand at a CAGR of 3% over the period 2022-2030. Emerging technologies and drug developments are driving the overactive bladder treatment market, driven by rising healthcare and infrastructure costs and an increasing number of elderly.
Additionally, the advent of combination therapies and increasing drug approvals will stimulate the overactive bladder treatment market. Also, the continuous therapeutic advancement in the pharmaceutical industry is driving the demand for overactive bladder, which is expected to drive the growth of the global overactive bladder treatment market.
Oxybutynin is valued by pharmacists driving global market growth primarily due to its affordability, superior efficacy and low adherence to OAB treatment. Botox treatment accelerates healing because Botox is inexpensive even in the hospital under general anesthesia.
However, it can also be done under local anesthesia. Also, Botox is a step and does not require a foreign body implant. Botox treatment is an acceptable treatment for doctors and requires less additional skill than cystoscopy. Botox is considered safe and the only side effect is that 6% of cases require a temporary catheter and 18% of cases require urological care. Depending on the type of treatment, NMS treatment leads to higher growth and should not replace leakage efficiency due to higher drying rates, higher zero pillow use, and better frequency/urgency. Also, NMS treatment is more comprehensive than Botox treatment and is a restorative treatment that restores the patients function. More complications (about 20%) occur with NMS. This usually includes unwanted irritation and pain at the implant site.
REPORT SCOPE :
Global Overactive Bladder Treatment Market (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive Bladder Treatment Market Forecast by Size, Growth, Price, etc. of Mirabegron • Treatment Analysis: Botox, NMS Therapy, PTNS.
REGIONAL ANALYSIS :
North America, Asia Pacific, Europe and the rest of the world (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive bladder treatment market-size, growth, forecast, by value • by drug analysis : Oxybutynin, Tolterodine, Trospio, Solifenacin, Mirabegron, others • Analysis by therapy: BOTOX, NMS therapy, PTNS.
COUNTRY ANALYSIS:
United States, Canada, Mexico, India, China, Japan, Germany, France, Italy, Spain (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive bladder treatment market: scale, growth , Prognosis, by value • Analysis by drug: Oxybutynin, Tolterodine, Trospio, Solinasine, Mirabegron, others • Analysis by therapy: BOTOX, NMS therapy, PTNS. "
Sanofi S.A., Macleod’s pharmaceuticals Ltd., Apotex, Axonics modulation technologies, Intas Pharmaceuticals, Teva Pharmaceuticals, Laborie, Pfizer Inc., Allergan, Astellas Pharma Inc.
Related Reports
Proof of Quality & Reliability
